PPARs and their Effects on the Cardiovascular System

REFERENCES

• Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507–514.
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79–82.
   PubMed Web of Science ®Google Scholar
• Delerive P, Martin-Nizard F, Chinetti G, Peroxisome proliferator-activated receptor activators inhibit thrombin induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999a; 85:394–402.
   PubMed Web of Science ®Google Scholar
• Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C.The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator activated receptor α. Molecular Endocrinol 2004;18:1906–1918.
   PubMed Web of Science ®Google Scholar
• Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Bioc Biophys Res Comm 1998;2:370–374.
   Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circ 1998a; 98:2088–2093.
   PubMed Web of Science ®Google Scholar
• Chinetti G, Griglio S, Antonucci M, Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273:25573–25580.
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev 1999;20(5):649–688.
   PubMed Web of Science ®Google Scholar
• Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421–424.
   PubMed Web of Science ®Google Scholar
• Chait A, Brazg RL, Tribble DL. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern. B Am J Med 1993;94:350–356.
   PubMed Web of Science ®Google Scholar
• Mandard S, M¨uller M, Kersten S. Peroxisome proliferator-activated receptor α target genes. Cell Mol Life Sci 2004;61: 393–416.
   PubMed Web of Science ®Google Scholar
• Patsouris D, Mandard S, Voshol PJ., PPARα governs glycerol metabolism. J Clin Invest 2004;114:94–103.
   PubMed Web of Science ®Google Scholar
• Barbier O, Villeneuve L, Bocher V, The UDP glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene. J Biol Chem 2003; 278:13975–13983.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571–580.
   PubMed Web of Science ®Google Scholar
• Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proceedings of the National Academy of Sciences of the United States of America 1997; 94:4312–4317.
   PubMed Web of Science ®Google Scholar
• Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinol 1994;135:798–800.
   PubMed Web of Science ®Google Scholar
• Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097–1103.
   PubMed Web of Science ®Google Scholar
• Bell DSH. β-cell rejuvenation with thiazolidinediones. Am J Med 2003;115:20–23.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. The New Engl J Med 2004;351:1106–1118.
   PubMed Web of Science ®Google Scholar
• Al-Khalili L, Forsgren M, Kannisto K, Zierath JR, Lönnqvist F, Krook A. Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor γ co-activator 1. Diabetologia 2005;48:1173–1179.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Lazar MA. The many faces of PPARγ. Cell 2005;123:993–999.
   PubMed Web of Science ®Google Scholar
• Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertension 2004;22:2253–2261.
   PubMed Web of Science ®Google Scholar
• Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 2001;98: 5306–5311.
   PubMed Web of Science ®Google Scholar
• Barish GD, Narkar VA, Evans RM. PPAR δ: a dagger in the heart of the metabolic Syndrome. J Clin Invest 2006;116: 590–597.
   PubMed Web of Science ®Google Scholar
• Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Sci 2003;302:453–457.
   PubMed Web of Science ®Google Scholar
• Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proceedings of the National Academy of Sciences of the United States of America 2002;99:2613–2618.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2000;97:13275–13280.
   PubMed Web of Science ®Google Scholar
• Di-Pöı N, Michalik L, Tan NS, Desvergne B, Wahli W. The anti-apoptotic role of PPARβ contributes to efficient skin wound healing. J Steroid Bioc Mol Biol 2003;85: 257–265.
   PubMed Web of Science ®Google Scholar
• Liou JY, Lee S, Ghelani D, Matijevie-Aleksie N, Wu KK. Protection of endothelial survival by peroxisome proliferator activated receptor- δ mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006;26:1481–1487.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Sci 1993a;259:87–91.
   PubMed Web of Science ®Google Scholar
• Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Bioc Soc Trans 2005;33:1078–1081.
   PubMed Web of Science ®Google Scholar
• Florez H, Castillo-Florez S, Mendez A, Casanova-Romero, P., Larreal-Urdaneta, C., Lee, D. and Goldberg, R. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006;71:92–100.
   PubMed Web of Science ®Google Scholar
• Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97: 3A–11A.
   PubMed Web of Science ®Google Scholar
• Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. The Am J Clin Nutr 2006;83:461S–465S.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammatory pathways and insulin action. Intl J Obesity Related Metabolic Disorders 2003;27:S53–S55.
   PubMed Web of Science ®Google Scholar
• Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531–1537.
   PubMed Web of Science ®Google Scholar
• Nguyen MTA, Satoh H, Favelyukis S, JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280: 35361–35371.
   PubMed Web of Science ®Google Scholar
• Gao Z, Hwang D, Bataille F, Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J Biol Chem 2002;277:48115–48121.
   PubMed Web of Science ®Google Scholar
• Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006;38:64–80.
   PubMed Web of Science ®Google Scholar
• Delerive P, De Bosscher K, Besnard S, Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 1999b;274:32048–32054.
   PubMed Web of Science ®Google Scholar
• Gervois P, Vu-Dac N, Kleemann R, Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β. J Biol Chem 2001;276:33471–33477.
   PubMed Web of Science ®Google Scholar
• Gervois P, Kleemann R, Pilon A, Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator activated receptor-α activator fenofibrate. J Biol Chem 2004;279:16154–16160.
   PubMed Web of Science ®Google Scholar
• Stienstra R, Duval C, Muller M, Kersten S. PPARs, Obesity, and Inflammation PPAR. New York, NY: Hindawi Publishing Corporation, Volume 2007, Article ID 95974.
   Google Scholar
• Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–1830.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 2001;276:41245–41254.
   PubMed Web of Science ®Google Scholar
• Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ Res 2002;91: 427–433.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Wu HD, Willerson JT, and Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circ 2000; 101:235–238.
   PubMed Web of Science ®Google Scholar
• Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003;113:159–170.
   PubMed Web of Science ®Google Scholar
• Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE and Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nature Med 2004;10:1245–1250.
   PubMed Web of Science ®Google Scholar
• Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circ 2000;101:1311–1318.
   PubMed Web of Science ®Google Scholar
• Law RE, Hsueh WA. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001;21:1891–1895.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82–86.
   PubMed Web of Science ®Google Scholar
• Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor γ(PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999; 66:733–739.
   PubMed Web of Science ®Google Scholar
• Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circ 2002;105:2296–2302.
   PubMed Web of Science ®Google Scholar
• Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999;21:76–83.
   PubMed Web of Science ®Google Scholar
• Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, O’Rahilly S. Dominant negative mutations in human PPAR-γ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880–883.
   PubMed Web of Science ®Google Scholar
• Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension 2001; 38:249–254.
   PubMed Web of Science ®Google Scholar
• Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003;23:45–51.
   PubMed Web of Science ®Google Scholar
• Tabernero A, Schoonjans C, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator activated receptor α protects against myocardial ischemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002;2:1–10.
   PubMedGoogle Scholar
• Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternak A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circ 1997;96:2137–2143.
   PubMed Web of Science ®Google Scholar
• Ericsson C, Hansten A, Nilsson J, Grip L, Svane B de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849–853.
   PubMed Web of Science ®Google Scholar
• Dandona P. Endothelium, Inflamation, and diabetes. Curr Diab Rep 2002;2(4):311–315.
   PubMedGoogle Scholar
• Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann, Neves MF, Schiffrin EL. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002;40:866–871.
   PubMed Web of Science ®Google Scholar
• Ikeda U, Shimpo M, Murakami Y, Shimada K. Peroxidsome proliferator-activated receptor-g ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension 2000;35:1232–1236.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Duriez P, Staels B. Peroxisome proliferasator-activated receptor alpha activators regulates gene governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245–257.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Rodriguez-Pascual F, Klatt P, Lamas S, Perez-Sala D. PPAR agonists amplify iNOS expression while inhibiting NFkB: Implications for mesangial cell activation by cytokines. Am Soc Nephrol 2002;13(9): 2223–2231.
   PubMed Web of Science ®Google Scholar
• Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor-γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:52–57.
   PubMed Web of Science ®Google Scholar
• Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circ 2003;108:2805–2811.
   PubMed Web of Science ®Google Scholar
• Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168–1178.
   PubMed Web of Science ®Google Scholar
• Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, repress nuclear factor–kappa B signaling and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833–32841.
   PubMed Web of Science ®Google Scholar